

### **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010


#### NXNL1 RABBIT PAB

货号: S218838 产品全名: NXNLI 兔多抗 基因符号 RDCVF; TXNL6 UNIPROT ID: Q96CM4 (Gene Accession - BC014127) 背景: Retinitis pigmentosa (RP) is a disease that leads to blindness by degeneration of cone photoreceptors. Rods produce factors required for cone viability. The protein encoded by this gene is one of those factors and is similar to a truncated form of thioredoxin. This gene has been proposed to have therapeutic value against RP. 抗原: Fusion protein of human NXNL1 经过测试的应用: ELISA, WB, IHC 推荐稀释比: IHC: 20-100;WB: 200-1000;ELISA: 5000-10000 种属反应性: Rabbit 克隆性: Rabbit Polyclonal 亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human 成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol 研究领域: Cell Biology 储存和运输: Store at -20°C. Avoid repeated freezing and thawing




## **Product Description**


Pioneering GTPase and Oncogene Product Development since 2010



Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 218838(NXNL1 Antibody) at a dilution of 1/30(Nucleus). In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 218838(Anti-NXNL1 Antibody) at dilution 1/30.




The image on the left is immunohistochemistry of paraffinembedded Human esophagus cancer tissue using 218838(Anti-NXNL1 Antibody) at a dilution of 1/30.



In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with fusion protein and then with D225322(Anti-NXNL1 Antibody) at dilution 1/30.

#### kDa



Gel: 12%SDS-PAGE, Lysate: 40 µg; Lane: A549 cell lysate ; Primary antibody: 218838(NXNL1 Antibody) at dilution 1/200; Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution; Exposure time: 30 seconds



# **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010